THRB
ENSG00000151090
Target class
Nuclear receptor
Chromosome
3
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- Yes
- Target name
- THRB
- Gene name
- Thyroid hormone receptor beta
- Gene symbol
- THRB
- Protein name
- Thyroid hormone receptor beta (Nuclear receptor subfamily 1 group A member 2) (c-erbA-2) (c-erbA-beta)
- THRB1
- THRB2
- NR1A2
- THR1
- ERBA-BETA
- GRTH
- TRbeta
- TRb
- c-erbA-beta
- c-erbA-2
- THRbeta
- TRbeta1
- THRbeta1
- Thrbeta2
- ERBA2
- PRTH
- Gene biotype
- Protein coding
- Gene family
- Thyroid hormone receptors
- Target class
- Nuclear receptor
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 38.66
- Tissue specificity (Gini)
- 0.468
- Tissue specificity (tau)
- 0.819
- KEGG gene identifiers
- hsa:7068
- Protein interaction confidence
- 0.857207
- Protein interaction partners
- 29
- R-HSA-383280
- R-HSA-4090294
- End position
- 24495756
- Start position
- 24117153
- Chromosome
- 3
- Strand
- Reverse
- Nucleus.
- Nuclear bodies
- Tissue specificity (tau)
- 0.818505
- Expression inequality (Gini)
- 0.468045
Expression in transcripts per million
- Artery - Aorta
- 38.66
- Brain - Frontal Cortex (BA9)
- 26.19
- Artery - Tibial
- 24.2
- Pituitary
- 22.92
- Brain - Cortex
- 18.14
Expression in transcripts per million
- Artery - Aorta38.66
- Brain - Frontal Cortex (BA9)26.19
- Artery - Tibial24.2
- Pituitary22.92
- Brain - Cortex18.14
- Colon - Sigmoid15.88
- Artery - Coronary15.53
- Esophagus - Gastroesophageal Junction14.14
- Esophagus - Muscularis13.99
- Brain - Anterior cingulate cortex (BA24)13.45
- Bladder11.54
- Breast - Mammary Tissue10.31
- Adipose - Subcutaneous10.27
- Uterus10.17
- Cells - Cultured fibroblasts9.81
- Muscle - Skeletal8.86
- Colon - Transverse8.16
- Skin - Sun Exposed (Lower leg)7.46
- Adipose - Visceral (Omentum)7.26
- Skin - Not Sun Exposed (Suprapubic)7.09
- Brain - Nucleus accumbens (basal ganglia)6.55
- Brain - Amygdala6.37
- Prostate6.26
- Stomach5.71
- Vagina5.52
And 29 more, listed on the interactive page.
- GO:0002157
- GO:0006351
- GO:0042789
- GO:0045944
- GO:0097067
- GO:0005634
- GO:0005654
- GO:0016604
- GO:0001223
- GO:0003677
- GO:0004879
- GO:0005515
- GO:0019899
- GO:0070324
- GO:1990837
Related records
Trials (230)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia
- A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
- A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
- A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
- A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients
- A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
- A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism
- A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade
- A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood
- A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
- A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)
- A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects
- A Study of T3 Therapy in Patients With Hypothyroidism
- A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Drugs (10)
- Dextrothyroxine Thyroid hormone receptor agonist
- Dextrothyroxine sodium Thyroid hormone receptor agonist
- Eprotirome Thyroid hormone receptor beta-1 agonist
- Levothyroxine Thyroid hormone receptor agonist
- Levothyroxine sodium Thyroid hormone receptor agonist
- Liothyronine Thyroid hormone receptor agonist
- Liothyronine sodium Thyroid hormone receptor agonist
- MB07811 Thyroid hormone receptor beta-1 agonist
- Resmetirom Thyroid hormone receptor beta-1 agonist
- Tiratricol Thyroid hormone receptor agonist